Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
- Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
- “Forte achieved a major milestone by advancing FB-102 into the clinic and beating the timelines we targeted in our third quarter business update.
- Forte ended 2023 with approximately $37.1 million in cash and cash equivalents.
- Forte had approximately 36.3 million shares of common stock outstanding as of December 31, 2023.